Covetrus Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Covetrus şirketinin kazançları yıllık ortalama -7.8% oranında azalırken, Healthcare sektörünün kazançları yıllık 5.8% oranında artan oldu. Gelirler yıllık ortalama 7.1% oranında artan oldu.

Anahtar bilgiler

-7.8%

Kazanç büyüme oranı

-9.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi	15.7%
Gelir büyüme oranı	7.1%
Özkaynak getirisi	-0.9%
Net Marj	-0.3%
Son Kazanç Güncellemesi	30 Jun 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Covetrus nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

XTRA:2NJ Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 22	4,649	-13	723
31 Mar 22	4,621	-40	728
31 Dec 21	4,575	-54	714
30 Sep 21	4,575	-56	709
30 Jun 21	4,539	-90	714
31 Mar 21	4,376	-13	685
31 Dec 20	4,339	-26	698
30 Sep 20	4,225	-19	700
30 Jun 20	4,117	-940	630
31 Mar 20	4,100	-996	688
31 Dec 19	3,976	-980	661
30 Sep 19	3,871	-948	576
30 Jun 19	3,776	27	587
31 Mar 19	3,772	65	504
29 Dec 18	3,778	101	485
30 Sep 18	3,791	69	547
30 Jun 18	3,776	74	543
31 Mar 18	3,649	67	532
30 Dec 17	3,580	64	460
31 Dec 16	3,353	70	489
26 Dec 15	2,978	60	418

Kaliteli Kazançlar: 2NJ şu anda kârlı değil.

Büyüyen Kar Marjı: 2NJ şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 2NJ kârlı değildir ve zararlar son 5 yılda yılda 7.8% oranında artmıştır.

Büyüme Hızlandırma: 2NJ 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 2NJ kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( 30.9% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 2NJ hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -0.85% ) sahiptir.

Covetrus Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2022 earnings released: US$0.029 loss per share (vs US$0.23 loss in 2Q 2021)

Covetrus, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.12 loss in 1Q 2021)

Covetrus, Inc. to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Covetrus, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Recent updates

Covetrus, Inc. Announces Executive Appointments

Covetrus® Expands Role and Responsibilities for Dr. Link Welborn, Chief Veterinary Officer

Covetrus to Showcase Its Vetsuite Solution At VMX 2024

Covetrus Announces Management Changes

Covetrus, Inc. Files Form 15

Covetrus, Inc.(NasdaqGS:CVET) dropped from NASDAQ Composite Index

Covetrus Announces the Appointment of Michelle Bonfilio as Chief People Officer

Covetrus Appoints Margie B. Pritchard as General Counsel and Corporate Secretary

Covetrus, Inc. Announces Retirement of Matthew Foulston as Executive Vice President, Effective December 31, 2022

Saxena White P.A. Announces Settlement of Class Action on Behalf of Purchasers of Covetrus, Inc. Common Stock

Second quarter 2022 earnings released: US$0.029 loss per share (vs US$0.23 loss in 2Q 2021)

Covetrus, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Independent Director recently sold €674k worth of stock

Clayton, Dubilier & Rice, LLC and TPG Global, LLC offered to acquire remaining 75.8% stake in Covetrus, Inc. (NasdaqGS:CVET) $2.2 billion.

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.12 loss in 1Q 2021)

Covetrus® Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific

Covetrus, Inc. to Report Q1, 2022 Results on May 05, 2022

Covetrus, Inc., Annual General Meeting, May 11, 2022

High number of new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Covetrus, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Covetrus, Inc. Announces the Launch of Covetrus Pulse

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.34 loss in 3Q 2020)

VP, Chief Accounting Officer & Global Controller Laura Phillips has left the company

Director recently bought €99k worth of stock

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.41 profit in 2Q 2020)

Covetrus, Inc. (NasdaqGS:CVET) entered into a definitive agreement to acquire VCP.

Covetrus Enhances to Their Practice Management Software to Help Veterinary Clinics Compete Online and Deliver More Complete Healthcare

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.26 loss in 1Q 2020)

Independent Director recently sold €171k worth of stock

Covetrus, Inc. Announces the Addition of Stacey M.M. Shirra as Vice President of Global Talent Management

Revenue beats expectations

Full year 2020 earnings released: US$0.16 loss per share (vs US$9.52 loss in FY 2019)

Covetrus Appoints Link Welborn as Chief Veterinary Officer

Covetrus, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Covetrus Appoints Deborah Sharkey as Chief Consumer Officer

Covetrus, Inc.(NasdaqGS:CVET) dropped from Russell 1000 Growth-Defensive Index

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin